Andrew Long
Family Medicine · Kalkaska, MINPI 1558554808
Payments from drug & device makers
Across 106 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$480
- Boehringer Ingelheim$234
- Novo Nordisk$140
- Teleflex LLC$111
- Lilly USA, LLC$106
- Amgen$104
- plus $860 from 21 others
What the payments were for
- Food & beverage$2,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $480 |
| Boehringer Ingelheim | 11 | $234 |
| Novo Nordisk | 8 | $140 |
| Teleflex LLC | 1 | $111 |
| Lilly USA, LLC | 6 | $106 |
| Amgen | 7 | $104 |
| Pfizer | 6 | $96 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
| Abbott | 2 | $85 |
| Bayer | 4 | $78 |
| Johnson & Johnson | 2 | $57 |
| Alkermes, Inc. | 3 | $56 |
| AstraZeneca | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| GSK | 2 | $36 |
| RGH Enterprises LLC | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Vertex | 1 | $25 |
| Indivior Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,035 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 192 | $228,861 |
| MounjaroTirzepatide | 195 | $224,647 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $116,606 |
| TrulicityDulaglutide | 73 | $93,041 |
| FarxigaDapagliflozin Propanediol | 87 | $80,825 |
| EliquisApixaban | 70 | $80,029 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $64,715 |
| OzempicSemaglutide | 51 | $63,951 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $32,537 |
| XareltoRivaroxaban | 29 | $31,990 |
| MyrbetriqMirabegron | 32 | $29,233 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $21,793 |
| Novolog FlexpenInsulin Aspart | 52 | $18,160 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $17,245 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $16,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $106 | $317,688268 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $234 | $247,961216 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $36 | $138,399127 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $52 | $97,462119 claims |
| PfizerEliquis | $96 | $80,02970 claims |
| Novo NordiskOzempic | $140 | $63,95151 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $50 | $32,53729 claims |
| Johnson & JohnsonXarelto | $57 | $31,99029 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $29,23332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Kalkaska
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.